- Home
- DPRO vs PMCB Comparison
DPRO vs PMCB Comparison
Compare DPRO & PMCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DPRO
- PMCB
- Stock Information
- Founded
- DPRO 1998
- PMCB 1996
- Country
- DPRO Canada
- PMCB United States
- Employees
- DPRO N/A
- PMCB N/A
- Industry
- DPRO Aerospace
- PMCB Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DPRO Industrials
- PMCB Health Care
- Exchange
- DPRO Nasdaq
- PMCB Nasdaq
- Market Cap
- DPRO 10.4M
- PMCB 7.1M
- IPO Year
- DPRO N/A
- PMCB N/A
- Fundamental
- Price
- DPRO $1.77
- PMCB $1.03
- Analyst Decision
- DPRO Strong Buy
- PMCB
- Analyst Count
- DPRO 2
- PMCB 0
- Target Price
- DPRO $6.00
- PMCB N/A
- AVG Volume (30 Days)
- DPRO 247.4K
- PMCB 9.8K
- Earning Date
- DPRO 05-08-2025
- PMCB 03-17-2025
- Dividend Yield
- DPRO N/A
- PMCB N/A
- EPS Growth
- DPRO N/A
- PMCB N/A
- EPS
- DPRO N/A
- PMCB 1.29
- Revenue
- DPRO $4,716,450.00
- PMCB N/A
- Revenue This Year
- DPRO $94.01
- PMCB N/A
- Revenue Next Year
- DPRO $95.14
- PMCB N/A
- P/E Ratio
- DPRO N/A
- PMCB $0.79
- Revenue Growth
- DPRO 7.90
- PMCB N/A
- 52 Week Low
- DPRO $1.55
- PMCB $1.00
- 52 Week High
- DPRO $7.01
- PMCB $2.42
- Technical
- Relative Strength Index (RSI)
- DPRO 39.67
- PMCB 39.95
- Support Level
- DPRO $1.63
- PMCB $1.00
- Resistance Level
- DPRO $1.93
- PMCB $1.12
- Average True Range (ATR)
- DPRO 0.11
- PMCB 0.07
- MACD
- DPRO 0.02
- PMCB 0.01
- Stochastic Oscillator
- DPRO 46.67
- PMCB 14.94
About DPRO Draganfly Inc.
Draganfly Inc is a Canada based company. It is engaged in the provision of engineering services and the manufacture of commercial unmanned vehicle systems and software. The company operates in Canada, the United States, and Internationally. The three segments are Drones, Vital (Vital Intelligence), and Corporate. The Drones segment derives its revenue from products and services related to the sale of unmanned aerial vehicles (UAV). The Vital segment derives its revenue from the sale of products that measure vitals to help detect symptoms from large groups of people from a distance. The Corporate segment includes all costs not directly associated with the Drone and Vital segments. It generates majority of its revenue from Drones segment.
About PMCB PharmaCyte Biotech Inc.
PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.